Published in Protein Sci on March 01, 2005
IL-6 as a keystone cytokine in health and disease. Nat Immunol (2015) 2.14
Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol (2006) 1.65
The composition and signaling of the IL-35 receptor are unconventional. Nat Immunol (2012) 1.63
A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 1.44
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem (2011) 1.29
Sensitivity analysis of intracellular signaling pathway kinetics predicts targets for stem cell fate control. PLoS Comput Biol (2007) 1.22
Inactivation of cardiotrophin-like cytokine, a second ligand for ciliary neurotrophic factor receptor, leads to cold-induced sweating syndrome in a patient. Proc Natl Acad Sci U S A (2006) 1.05
An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem (2012) 1.01
N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. J Biol Chem (2009) 0.98
A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11. PLoS One (2008) 0.96
Urokinase and its receptors in chronic kidney disease. Front Biosci (2008) 0.94
Regulation of a lymphocyte-endothelial-IL-6 trans-signaling axis by fever-range thermal stress: hot spot of immune surveillance. Cytokine (2007) 0.94
Constitutively active mutant gp130 receptor protein from inflammatory hepatocellular adenoma is inhibited by an anti-gp130 antibody that specifically neutralizes interleukin 11 signaling. J Biol Chem (2012) 0.91
Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling. J Biol Chem (2013) 0.88
A designer hyper interleukin 11 (H11) is a biologically active cytokine. BMC Biotechnol (2012) 0.87
Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation. Oncotarget (2014) 0.85
Interaction of the C-terminal tail of FliF with FliG from the Na+-driven flagellar motor of Vibrio alginolyticus. J Bacteriol (2014) 0.84
Conservation of functional sites on interleukin-6 and implications for evolution of signaling complex assembly and therapeutic intervention. J Biol Chem (2012) 0.82
Recombinant p35 from bacteria can form Interleukin (IL-)12, but Not IL-35. PLoS One (2014) 0.81
Different Soluble Forms of the Interleukin-6 Family Signal Transducer gp130 Fine-tune the Blockade of Interleukin-6 Trans-signaling. J Biol Chem (2016) 0.78
Interleukin 6/Wnt interactions in rheumatoid arthritis: interleukin 6 inhibits Wnt signaling in synovial fibroblasts and osteoblasts. Croat Med J (2016) 0.78
Cleavage Site Localization Differentially Controls Interleukin-6 Receptor Proteolysis by ADAM10 and ADAM17. Sci Rep (2016) 0.77
Alternative intronic polyadenylation generates the interleukin-6 trans-signaling inhibitor sgp130-E10. J Biol Chem (2014) 0.77
Proteolytic Origin of the Soluble Human IL-6R In Vivo and a Decisive Role of N-Glycosylation. PLoS Biol (2017) 0.75
A mathematical model for selective differentiation of neural progenitor cells on micropatterned polymer substrates. Math Biosci (2012) 0.75
Dynamics of fluorescence marker concentration as a probe of mobility. Biophys J (1976) 9.67
Single-molecule imaging of EGFR signalling on the surface of living cells. Nat Cell Biol (2000) 6.63
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol (1997) 5.38
Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor. Science (1988) 4.93
The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood (2003) 3.51
Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. Science (1999) 3.03
Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complex. Science (2003) 2.87
Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 2.83
I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion. Nat Biotechnol (1997) 2.47
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem (2001) 2.30
Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol (1992) 1.94
Structure of an extracellular gp130 cytokine receptor signaling complex. Science (2001) 1.94
Dual oncostatin M (OSM) receptors. Cloning and characterization of an alternative signaling subunit conferring OSM-specific receptor activation. J Biol Chem (1996) 1.89
Fluorescence intensity multiple distributions analysis: concurrent determination of diffusion times and molecular brightness. Biophys J (2000) 1.75
The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med (1996) 1.65
Protein secondary structure from circular dichroism spectroscopy. Combining variable selection principle and cluster analysis with neural network, ridge regression and self-consistent methods. J Mol Biol (1994) 1.59
High affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem (1994) 1.57
The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta (2002) 1.53
Sympathetic neurons can produce and respond to interleukin 6. Proc Natl Acad Sci U S A (1998) 1.51
Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine (1992) 1.47
Two distinct and independent sites on IL-6 trigger gp 130 dimer formation and signalling. EMBO J (1995) 1.39
Convergent mechanisms for recognition of divergent cytokines by the shared signaling receptor gp130. Mol Cell (2003) 1.38
Neuropoietin, a new IL-6-related cytokine signaling through the ciliary neurotrophic factor receptor. Proc Natl Acad Sci U S A (2004) 1.36
Interleukin-6 and soluble interleukin-6 receptor: direct stimulation of gp130 and hematopoiesis. Blood (1998) 1.32
The importance of shedding of membrane proteins for cytokine biology. Eur Cytokine Netw (2000) 1.21
Cardiotrophin-1, a cytokine present in embryonic muscle, supports long-term survival of spinal motoneurons. Neuron (1996) 1.19
Seeing the light: preassembly and ligand-induced changes of the interferon gamma receptor complex in cells. Mol Cell Proteomics (2002) 1.18
Miniaturized HTS technologies - uHTS. Drug Discov Today (2001) 1.17
Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med (1997) 1.13
Neural activities of IL-6-type cytokines often depend on soluble cytokine receptors. Eur J Neurosci (1999) 1.11
Novel path to activation of vascular smooth muscle cells: up-regulation of gp130 creates an autocrine activation loop by IL-6 and its soluble receptor. J Immunol (1999) 1.10
Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6. Stem Cells (2002) 1.09
Activation of the signal transducer glycoprotein 130 by both IL-6 and IL-11 requires two distinct binding epitopes. J Immunol (1999) 1.06
The hepatic interleukin-6 receptor. Down-regulation of the interleukin-6 binding subunit (gp80) by its ligand. FEBS Lett (1992) 1.03
IL-6 type cytokine receptor complexes: hexamer, tetramer or both? Biol Chem (1999) 1.01
Receptor recognition sites of cytokines are organized as exchangeable modules. Transfer of the leukemia inhibitory factor receptor-binding site from ciliary neurotrophic factor to interleukin-6. J Biol Chem (1999) 0.97
Soluble human interleukin-6 receptor. Expression in insect cells, purification and characterization. Eur J Biochem (1995) 0.96
Coordination of interleukin-6 biology by membrane bound and soluble receptors. Adv Exp Med Biol (2001) 0.94
Influence of interleukin-6 (IL-6) dimerization on formation of the high affinity hexameric IL-6.receptor complex. J Biol Chem (1996) 0.92
Determination of the tryptophan:tyrosine ratio in proteins. Anal Biochem (1993) 0.92
Single-molecule detection technologies in miniaturized high throughput screening: binding assays for g protein-coupled receptors using fluorescence intensity distribution analysis and fluorescence anisotropy. J Biomol Screen (2001) 0.91
Signaling of type II oncostatin M receptor. J Biol Chem (1997) 0.89
Two different epitopes of the signal transducer gp130 sequentially cooperate on IL-6-induced receptor activation. J Immunol (2000) 0.89
GP130 stimulation and the maintenance of stem cells. Trends Biotechnol (2002) 0.85
Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity. EMBO J (1996) 0.79
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta (2011) 5.72
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity (2004) 4.48
Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 4.12
The disintegrin-like metalloproteinase ADAM10 is involved in constitutive cleavage of CX3CL1 (fractalkine) and regulates CX3CL1-mediated cell-cell adhesion. Blood (2003) 3.51
CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med (2006) 3.11
The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo. J Clin Invest (2005) 2.91
Transcriptional profiling identifies Id2 function in dendritic cell development. Nat Immunol (2003) 2.91
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest (2011) 2.83
Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection. Hepatology (2009) 2.48
Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem (2003) 2.26
ADAM17: a molecular switch to control inflammation and tissue regeneration. Trends Immunol (2011) 2.19
The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. J Immunol (2004) 2.19
IL-6 transsignaling: the in vivo consequences. J Interferon Cytokine Res (2005) 2.17
The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets (2007) 2.17
Fever-range thermal stress promotes lymphocyte trafficking across high endothelial venules via an interleukin 6 trans-signaling mechanism. Nat Immunol (2006) 2.05
Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem (2003) 2.05
Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother (2011) 2.01
Soluble interleukin-15 receptor alpha (IL-15R alpha)-sushi as a selective and potent agonist of IL-15 action through IL-15R beta/gamma. Hyperagonist IL-15 x IL-15R alpha fusion proteins. J Biol Chem (2005) 2.01
Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci (2005) 2.00
Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood (2007) 1.92
Selective blockade of interleukin-6 trans-signaling improves survival in a murine polymicrobial sepsis model. Crit Care Med (2011) 1.87
Critical role of the disintegrin metalloprotease ADAM17 for intestinal inflammation and regeneration in mice. J Exp Med (2010) 1.80
Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol (2007) 1.78
Maintenance of pluripotency in human embryonic stem cells is STAT3 independent. Stem Cells (2004) 1.73
The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. J Immunol (2010) 1.70
Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest (2003) 1.69
Soluble IL-6 receptor governs IL-6 activity in experimental arthritis: blockade of arthritis severity by soluble glycoprotein 130. J Immunol (2003) 1.68
Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol (2006) 1.65
G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J Immunol (2009) 1.65
The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury. J Clin Invest (2005) 1.63
Differentially regulated GPVI ectodomain shedding by multiple platelet-expressed proteinases. Blood (2010) 1.56
Uncovering the evolutionary history of innate immunity: the simple metazoan Hydra uses epithelial cells for host defence. Dev Comp Immunol (2008) 1.55
The role of soluble receptors in cytokine biology: the agonistic properties of the sIL-6R/IL-6 complex. Biochim Biophys Acta (2002) 1.53
Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol (2012) 1.49
IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol (2008) 1.48
L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowth. Mol Cell Biol (2005) 1.47
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest (2011) 1.46
VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J Exp Med (2010) 1.45
A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 1.44
Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol (2008) 1.42
In vivo evidence suggesting reciprocal renal hypoxia-inducible factor-1 upregulation and signal transducer and activator of transcription 3 activation in response to hypoxic and non-hypoxic stimuli. Clin Exp Pharmacol Physiol (2013) 1.41
IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol (2010) 1.39
Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev (2012) 1.38
A key role for gp130 expressed on peripheral sensory nerves in pathological pain. J Neurosci (2009) 1.37
Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood (2007) 1.37
Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol (2010) 1.36
The soluble Interleukin 6 receptor: generation and role in inflammation and cancer. Eur J Cell Biol (2010) 1.35
Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol (2009) 1.35
Depletion of cellular cholesterol and lipid rafts increases shedding of CD30. J Immunol (2004) 1.34
IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res (2010) 1.31
PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene (2005) 1.30
Species specificity of ADAM10 and ADAM17 proteins in interleukin-6 (IL-6) trans-signaling and novel role of ADAM10 in inducible IL-6 receptor shedding. J Biol Chem (2011) 1.29
Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arterioscler Thromb Vasc Biol (2011) 1.29
Interleukin-6 trans-signaling in inflammatory bowel disease. Cytokine Growth Factor Rev (2006) 1.29
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem (2011) 1.29
IL-6 trans-signaling promotes pancreatitis-associated lung injury and lethality. J Clin Invest (2013) 1.28
Interleukin-31 and oncostatin-M mediate distinct signaling reactions and response patterns in lung epithelial cells. J Biol Chem (2006) 1.27
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25
The transcription factor IFN regulatory factor-4 controls experimental colitis in mice via T cell-derived IL-6. J Clin Invest (2008) 1.24
Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum Mol Genet (2013) 1.23
Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J (2006) 1.23
Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages. Gastroenterology (2011) 1.20
IL6/sIL6R complex contributes to emergency granulopoietic responses in G-CSF- and GM-CSF-deficient mice. Blood (2007) 1.20
Inhibition of T cell apoptosis in the aqueous humor of patients with uveitis by IL-6/soluble IL-6 receptor trans-signaling. J Immunol (2004) 1.17
Opposing roles of gp130-mediated STAT-3 and ERK-1/ 2 signaling in liver progenitor cell migration and proliferation. Hepatology (2007) 1.15
Allosteric beta-propeller signalling in TolB and its manipulation by translocating colicins. EMBO J (2009) 1.15
Interleukin-6 in sepsis and capillary leakage syndrome. J Interferon Cytokine Res (2011) 1.14
HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood (2012) 1.14
Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J Virol (2009) 1.14
Lack of gp130 expression in hepatocytes promotes liver injury. Gastroenterology (2003) 1.12
Delivery of hyper-interleukin-6 to the injured spinal cord increases neutrophil and macrophage infiltration and inhibits axonal growth. J Comp Neurol (2002) 1.11
Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci (2014) 1.10
Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets (2012) 1.10
The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J Exp Med (2008) 1.10
Ligand/receptor signaling threshold (LIST) model accounts for gp130-mediated embryonic stem cell self-renewal responses to LIF and HIL-6. Stem Cells (2002) 1.09
Elastin-like polypeptides revolutionize recombinant protein expression and their biomedical application. Trends Biotechnol (2009) 1.08
Activation of interleukin-6-induced glycoprotein 130/signal transducer and activator of transcription 3 pathway in mesenchymal stem cells enhances hepatic differentiation, proliferation, and liver regeneration. Liver Transpl (2010) 1.08
The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem (2002) 1.08
Functional characterization of a soluble gp130 isoform and its therapeutic capacity in an experimental model of inflammatory arthritis. Arthritis Rheum (2006) 1.07
ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. Biochim Biophys Acta (2009) 1.07
Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis. EMBO Mol Med (2012) 1.07
The substrate degradome of meprin metalloproteases reveals an unexpected proteolytic link between meprin β and ADAM10. Cell Mol Life Sci (2012) 1.05
Role of interleukin-6 for LV remodeling and survival after experimental myocardial infarction. FASEB J (2003) 1.05
Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect. J Gene Med (2012) 1.04
Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J Biol Chem (2003) 1.04
Developing mRNA-vaccine technologies. RNA Biol (2012) 1.04
Murine liver antigen presenting cells control suppressor activity of CD4+CD25+ regulatory T cells. Hepatology (2005) 1.03
Sleep enhances IL-6 trans-signaling in humans. FASEB J (2006) 1.03